ROCKVILLE, Md., Nov. 1, 2016 /PRNewswire/ -- Optimal Research announces today their Just In Time platform for expanding patient access to clinical trials in oncology. Just In Time is offered as part of the Optimal Research Oncology network and is in response to Vice President Joe Biden's Moonshot initiative that calls for expanded access to clinical trials. This effort is designed to quickly engage patients that are in need of life saving treatment, while expediting key learnings in oncology in the hope for an eventual cure. Logo - http://photos.prnewswire.com/prnh/20161031/434288LOGO The science, data and research results are trapped in silos, preventing faster progress and greater reach to patients. It is not just about developing game changing treatments, it's about delivering them to those who need them - Joe Biden, Cancer Moonshot Just in Time is an 'on demand' delivery of cancer treatment though clinical research. Currently, less than 5% of the population participates in clinical trials due to issues around access and availability. For oncologists in the Optimal Research network, a trial can be initiated in as few as ten days for even one qualifying patient. The Just In Time, or JIT platform, reduces redundancies often found in the startup of clinical trials, and streamlines the process through integrated systems. This offering allows local oncologists to treat patients in their own hometown without the need to travel great distances to large institutions for care. We have taken up the challenge of expanded access in a unique and exciting way, and we look forward to furthering the vision of Vice President Biden in changing the trajectory of cancer research - Krystyna Kowalczyck, COO Optimal Research November is national lung cancer awareness month and Optimal Research is currently offering treatment in first line NSCLC (ALK+) through their JIT platform. For more information, please visit www.optimalsites.net/just-in-time Optimal Research provides clinical site solutions to pharmaceutical and biotech companies, medical device companies, and contract research organizations (CROs) seeking research sites to conduct clinical research studies in a high quality manner.